SMAD3 and glioblastoma: Prior studies have unveiled LIF as a downstream target of TGFβ signaling and SMAD2/3 binds to LIF promoter and activates its transcription to promote glioblastoma CSCs stemness.[28] This different preferential SMAD3 binding at LIF‐SE or promoter between our results from HNSCC and other cancers might be due to diverse genetic background and structure, disease etiology, and others.